Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
12.61
+0.53 (4.39%)
At close: Jan 29, 2026, 4:00 PM EST
12.61
0.00 (0.00%)
After-hours: Jan 29, 2026, 4:04 PM EST
Benitec Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
427.00M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | 75.00K | 2.00K | 2.74% |
| Jun 30, 2022 | 73.00K | 14.00K | 23.73% |
| Jun 30, 2021 | 59.00K | -43.00K | -42.16% |
| Jun 30, 2020 | 102.00K | -12.10M | -99.16% |
| Jun 30, 2019 | 12.20M | 8.81M | 259.85% |
| Jun 30, 2018 | 3.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Entrada Therapeutics | 61.52M |
| Assembly Biosciences | 37.19M |
| Aclaris Therapeutics | 15.74M |
| Lineage Cell Therapeutics | 10.82M |
| NovaBay Pharmaceuticals | 10.30M |
| Absci | 2.82M |
| vTv Therapeutics | 17.00K |
BNTC News
- 18 days ago - Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response - GlobeNewsWire
- 2 months ago - Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 3 months ago - Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering - GlobeNewsWire
- 3 months ago - Benitec Biopharma Inc. Announces Proposed Public Offering - GlobeNewsWire
- 3 months ago - Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301 - GlobeNewsWire
- 3 months ago - Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewsWire
- 4 months ago - Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 10 months ago - Benitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy Developer - Seeking Alpha